Phillip P. Sharp
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Ubiquitin and proteasome pathways, Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments
Most-Cited Works
- → A SARS-CoV-2 protein interaction map reveals targets for drug repurposing(2020)4,813 cited
- → A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing(2020)453 cited
- → Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and Zika Virus Pathogenesis(2018)396 cited
- → CIS is a potent checkpoint in NK cell–mediated tumor immunity(2016)378 cited
- → A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production(2015)148 cited
- → BET bromodomain inhibitors: a patent review(2013)119 cited
- → BET inhibitors induce apoptosis through a MYC independent mechanism and synergise with CDK inhibitors to kill osteosarcoma cells(2015)118 cited
- → Consecutive Gold(I)-Catalyzed Cyclization Reactions of o-(Buta-1,3-diyn-1-yl-)-Substituted N-Aryl Ureas: A One-Pot Synthesis of Pyrimido[1,6-a]indol-1(2H)-ones and Related Systems(2013)53 cited
- → A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis(2019)50 cited
- → BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells(2016)36 cited